Cost-Benefit Analysis Set for Advate, Hemophilia A Treatment

Cost-Benefit Analysis Set for Advate, Hemophilia A Treatment
0
(0)

Prime Therapeutics and Takeda will work together to establish the value of Advate, relative to its costs and benefits, as a treatment for hemophilia A.

According to Prime, work comparing factors like total health care costs and emergency hospital visits allow the company to better evaluate and distinguish treatments may provide the best outcomes at competitive prices.

“Our work since pioneering such contracts over a decade ago has been targeted and intentional — and this agreement with Takeda is no different,” Kelly McGrail-Pokuta, vice president of trade relations and strategy, and chief trade relations officer at Prime, a medical claims processing company that also manages healthcare plans for its U.S. clients, said in a press release.

“Members with hemophilia need treatments that work for them at a reasonable price, and that’s exactly what drives this collaboration,” McGrail-Pokuta added.

Hemophilia A is caused by missing or defective factor VIII (FVIII), a protein that plays an integral role in blood clotting.

Advate is a recombinant (lab-made) form of this protein. The medication, which is administered by injection, is approved to control and prevent bleedings, as routine preventive therapy, and to manage bleedings around the time of surgery in adults and children with hemophilia A. Advate was developed by Shire, now part of Takeda, and first approved in the U.S. in 2003.

More treatments for hemophilia have become available in recent years, but Prime noted in its release that newer therapies can be costly. As such, it is important for healthcare companies to understand their relative costs and benefits.

Under the agreement, Prime and Takeda will evaluate clinical outcomes relative to cost for an established hemophilia A treatment. The companies will also develop a health plan remuneration model to better understand the costs associated with unsuccessful treatment, based on certain measurable medical price structures.

“Takeda has a rich heritage of serving patients and providing innovative medicines to those who need them. This agreement with Prime will help us continue to deliver on our promise to provide critically important treatments with personalized care approaches to fit each patient’s needs, and to demonstrate the treatment’s overall value,” said Richard Ascroft, Takeda’s senior vice president of managed markets and patient services.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 46

José holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • Roctavian Phase 3 trial data
  • non-viral gene therapy
  • Advate and costs v. benefits
  • TRM-201, funding

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?